Van Ree R, Van Leeuwen W A, Dieges P H, Van Wijk R G, De Jong N, Brewczyski P Z, Kroon A M, Schilte P P, Tan K Y, Simon-Licht I F, Roberts A M, Stapel S O, Aalberse R C
Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.
Clin Exp Allergy. 1997 Jan;27(1):68-74. doi: 10.1046/j.1365-2222.1997.d01-416.x.
IgE titres tend to rise early after the start of immunotherapy, followed by a decline to pre-immunotherapy levels or lower.
We were interested to know whether the early increase in IgE antibodies includes new specificities of IgE, and whether these responses persist.
Sera of 64 patients undergoing grass pollen immunotherapy were tested for IgE against four purified grass pollen allergens: Lol p 1, 2, 3, and 5. At least two serum samples were taken, one before the start of therapy and one between 5 and 18 months after the first immunization (mean: 10 months).
The mean IgE responses to Lol p 1, 2 and 3 showed a moderate but not significant increase. In contrast, the mean IgE response to Lol p 5 showed a significant decrease of > 30%. IgE against total Lohum perenne pollen extract moderately increased (> 20%), showing that a RAST for total pollen is not always indicative for the development of IgE against its major allergens. For > 40% of the patients it was found that IgE against one or more of the four allergens increased, while IgE against the remaining allergen(s) decreased. For 10 sera the ratio of IgE titres against at least two allergens changed by at least a factor of 5. The changes in specific IgE also included conversions from negative (< 0.1 RU) to positive (0.6 to 5.0 RU) for five patients. For two patients, the induction of these 'new' IgE antibodies against major allergens was shown to result in a response that was persistent over several years.
Although active induction of new IgE specificities by immunotherapy was not really proven, the observations in this study indicate that monitoring of IgE against purified (major) allergens is necessary to evaluate changes in specific IgE in a reliable way.
免疫治疗开始后,IgE 滴度往往会在早期升高,随后降至免疫治疗前水平或更低。
我们想了解 IgE 抗体的早期升高是否包括新的 IgE 特异性,以及这些反应是否持续存在。
对 64 例接受草花粉免疫治疗的患者血清进行检测,以检测针对四种纯化草花粉过敏原(Lol p 1、2、3 和 5)的 IgE。至少采集两份血清样本,一份在治疗开始前,一份在首次免疫后 5 至 18 个月之间(平均:10 个月)。
对 Lol p 1、2 和 3 的平均 IgE 反应显示出适度但不显著的增加。相比之下,对 Lol p 5 的平均 IgE 反应显著下降超过 30%。针对多年生黑麦草总花粉提取物的 IgE 适度增加(>20%),表明总花粉的 RAST 并不总是能指示针对其主要过敏原的 IgE 的产生。发现超过 40%的患者针对四种过敏原中的一种或多种的 IgE 增加,而针对其余过敏原的 IgE 减少。对于 10 份血清,针对至少两种过敏原的 IgE 滴度之比至少改变了 5 倍。特异性 IgE 的变化还包括 5 名患者从阴性(<0.1 RU)转变为阳性(0.6 至 5.0 RU)。对于两名患者,针对主要过敏原的这些“新”IgE 抗体的诱导显示出持续数年的反应。
虽然免疫治疗对新的 IgE 特异性的主动诱导并未得到确切证实,但本研究中的观察结果表明,监测针对纯化(主要)过敏原的 IgE 对于以可靠方式评估特异性 IgE 的变化是必要的。